ArticleAbdominal radiology (New York)2025
Intrahepatic diffuse periportal hyperintensity patterns on hepatobiliary phase of gadoxetate-enhanced MRI: a non-invasive imaging biomarker for clinical stratification of liver injury.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MRI management of focal liver lesions: what a beginner cannot fail to know.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo evaluate the clinicoradiological significance of intrahepatic periportal hyperintensity (PHI) detected by gadoxetate-enhanced hepatobiliary phase (HBP) MRI and T2-weighted imaging (T2WI), and to assess its potential as a noninvasive imaging biomarker for clinical stratification of liver injury in patients with cirrhosis.
methodsThis retrospective study included 37 cirrhotic patients with intrahepatic diffuse PHI on HBP imaging, who underwent gadoxetate-enhanced MRI between October 2019 and November 2023. PHI patterns were classified into two groups based on the spatial concordance between periportal enhancement areas on HBP and periportal hyperintense areas on T2WI. The matching group (Type A, n = 21) demonstrated complete spatial overlap between the two sequences. The mismatching group, comprised Type B (n = 11), in which PHI on HBP was immediately outside of that on T2WI, and Type C (n = 5), in which PHI was present on HBP but absent on T2WI. Clinical etiologies and liver biochemical markers (ALT, AST, GGT, TBil, DBil, ALP, Alb, TP) were compared across PHI subtypes.
resultsType A PHI was predominantly associated with acute liver injury (e.g., acute viral hepatitis flares, drug-induced liver injury, autoimmune hepatitis), characterized by a strong ALT-AST correlation (r = 0.95, P < 0.001) and significantly elevated levels of ALT, AST, GGT, TBil, and DBil (all P < 0.001). In contrast, Types B and C PHI were primarily linked to chronic fibrotic conditions (e.g., HBV/HCV-related cirrhosis, primary biliary cholangitis, and primary sclerosing cholangitis), showing a strong TBil-DBil correlation (r = 0.95, P < 0.001) and moderately elevated ALP and Alb levels (P = 0.027 and P = 0.017, respectively). Receiver operating characteristic (ROC) analysis identified DBil > 37.5 μmol/L as the optimal threshold for differentiating Type A from Types B/C PHI (AUC = 0.922; sensitivity = 86.7%, specificity = 100%). Notably, HBP-doughnut nodules without arterial-phase hyperenhancement (APHE) were exclusively observed in the mismatching group (Type B: 4/11; Type C: 3/5), further supporting their association with chronic fibrotic changes.
conclusionPHI phenotyping based on HBP-T2WI spatial concordance enables accurate, noninvasive differentiation between acute inflammatory and chronic fibrotic liver injury in cirrhotic patients. When integrated with the DBil threshold, this imaging-based approach provides as a robust biomarker for clinical stratification of liver injury and may facilitate individualized diagnosis and therapeutic decision-making in chronic liver disease.
Indexed as
Identifiers
40358705What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.